Lowering high antibodies before stem cell transplant
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a special treatment to lower high levels of anti-HLA antibodies before a stem cell transplant. The goal is to help the transplant succeed and reduce the risk of rejection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are scheduled to receive a stem cell transplant from a donor.
- You are between 14 and 60 years old.
- You have high levels of anti-HLA antibodies (a test result showing MFI of 5000 or more).
- You do not have severe organ failure or an active infection.
- You and your family agree to the antibody testing and treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding dexamethasone, intravenous immunoglobulin, and extra donor cells can lower donor-specific antibodies in people receiving half-matched stem cell transplants. The goal is to help more patients safely get a transplant when fully matched donors aren't available.
This Phase 2 study tests an immune-suppressing treatment for people with sickle cell disease or beta-thalassemia who are preparing for a stem cell transplant from a donor. It aims to help the transplant work better by changing the immune response.
This study tests whether a special immune-resetting treatment can help patients who have developed too many antibodies against donor kidneys get access to a compatible kidney transplant. The treatment uses chemotherapy and stem cell transplantation to 'reset' your immune system so it stops rejecting potential donor kidneys.
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
Hear when a new High Titers of Anti-HLA Antibody (MFI ≥5000) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.